Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
July 10, 2024 – BioManufacturing, Biotechnology – Just- Evotec, biosimilars, partnership
- Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars
- Additional biosimilars potentially to be added to Sandoz development pipeline
- Further guarantees for Sandoz long-term commercial supply security
10 July 2024, Hamburg, Germany, and Seattle, WA, USA, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX , ISIN: DE0005664809; NASDAQ: EVO) today announced that its biologics segment, Just – Evotec Biologics, Inc., has expanded its strategic partnership with Sandoz. Just – Evotec Biologics will receive appropriate remuneration following early scientific validation, with further funding tied to achieving development milestones from 2025.
This expanded partnership solidifies Just – Evotec Biologics’ commitment to providing long-term commercial supply of biosimilars to Sandoz from its newly built J.POD biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. Sandoz secures further guarantees relating to long-term supply for patients with a reservation of significant commercial manufacturing capacity.
Since May 2023, Just – Evotec Biologics and Sandoz have been engaged in a multi-year technology partnership aimed at the rapid development and manufacturing of biosimilars. Leveraging its data-driven, fully integrated design capability and continuous manufacturing technology platform (J.DESIGN), Just – Evotec Biologics aims to deliver the highest product quality and cost efficiency to its partners. This collaboration aligns with Evotec’s mission to improve access to medicines for patients across the globe.
Dr Matthias Evers, chief business officer of Evotec, commented: “We are thrilled to expand our partnership with Sandoz, building on the successes we’ve achieved since the initial launch. Introducing additional molecules has the potential to enhance access for millions of patients, while commercial manufacturing from Toulouse will ensure the long-term supply of Sandoz’ biosimilar portfolio. This commercial supply aspect also validates our strategy to establish our second J.POD in Toulouse.”
About Just – Evotec Biologics:
Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Visit: www.just-evotecbiologics.com.
